RFK Jr. floats the idea of barring government scientists from publishing in leading medical journals due to “corruption”

Conversation with The Cancer Letter Podcast

Knight Cancer Institute receives record-setting $2B gift from the Knights—and self-governance within OHSU
Brian Druker returns to executive role as president of the new Knight Cancer Group

Phil and Penny Knight made a record-setting $2 billion gift to OHSU Knight Cancer Institute.

August 14, 2025

The Directors: Mary Beckerle and Neli Ulrich on delivering cancer care across five states
Honoring the Jon Huntsman Sr. political perspective: “I’m not a member of any party except the Cancer Party”

Mary Beckerle, a whitewater kayaker, has advice for all the folks in the cancer field: never catastrophize, never panic.

Trump administration broke law by canceling DEI research grants, GAO finds

The Government Accountability Office, an independent, non-partisan congressional watchdog agency, found that NIH violated the Impoundment Control Act of 1974 when it cancelled nearly 2,000 research grants in an effort to comply with several of President Donald Trump’s executive orders, including “Ending Radical And Wasteful Government DEI Programs And Preferencing” (The Cancer Letter, Jan 24, 2025).

HHS halts nearly $500M in mRNA-related vaccine contracts

The Department of Health and Human Services has announced the start of a reduction in its mRNA vaccine development activities under the Biomedical Advanced Research and Development Authority.

August 08, 2025

Vol.51 No.31

By Claire Marie Porter

Clinical Roundup

In phase III trial, epcoritamab regimen improves PFS in R/R follicular lymphoma

EPCORE FL-1 phase III trial results show that subcutaneous epcoritamab in combination with rituximab and lenalidomide reduced the risk of disease progression or death by 79% for patients with relapsed/refractory follicular lymphoma.

August 08, 2025

Vol.51 No.31

Oncologist biotech entrepreneur George Tidmarsh joins FDA as CDER director
His appointment came out of “proximity” to Makary and Bhattacharya

In a move that will have direct impact on approval of cancer drugs, George Francis Tidmarsh, an oncologist and a longtime pharmaceutical executive, was named director of the FDA Center for Drug Evaluation and Research.

July 25, 2025

Vol.51 No.29

By Claire Marie Porter

RFK Jr. floats the idea of barring government scientists from publishing in leading medical journals due to “corruption”

YOU MAY BE INTERESTED IN

Knight Cancer Institute receives record-setting $2B gift from the Knights—and self-governance within OHSU
Brian Druker returns to executive role as president of the new Knight Cancer Group

The Directors: Mary Beckerle and Neli Ulrich on delivering cancer care across five states
Honoring the Jon Huntsman Sr. political perspective: “I’m not a member of any party except the Cancer Party”

Trump administration broke law by canceling DEI research grants, GAO finds

HHS halts nearly $500M in mRNA-related vaccine contracts

In phase III trial, epcoritamab regimen improves PFS in R/R follicular lymphoma

Oncologist biotech entrepreneur George Tidmarsh joins FDA as CDER director
His appointment came out of “proximity” to Makary and Bhattacharya

Renew today!

Subscriber content

Never miss an issue!

Login

RFK Jr. floats the idea of barring government scientists from publishing in leading medical journals due to “corruption”

YOU MAY BE INTERESTED IN

Knight Cancer Institute receives record-setting $2B gift from the Knights—and self-governance within OHSUBrian Druker returns to executive role as president of the new Knight Cancer Group

The Directors: Mary Beckerle and Neli Ulrich on delivering cancer care across five statesHonoring the Jon Huntsman Sr. political perspective: “I’m not a member of any party except the Cancer Party”

Trump administration broke law by canceling DEI research grants, GAO finds

HHS halts nearly $500M in mRNA-related vaccine contracts

In phase III trial, epcoritamab regimen improves PFS in R/R follicular lymphoma

Oncologist biotech entrepreneur George Tidmarsh joins FDA as CDER directorHis appointment came out of “proximity” to Makary and Bhattacharya

Never miss an issue!

Login

Knight Cancer Institute receives record-setting $2B gift from the Knights—and self-governance within OHSU
Brian Druker returns to executive role as president of the new Knight Cancer Group

The Directors: Mary Beckerle and Neli Ulrich on delivering cancer care across five states
Honoring the Jon Huntsman Sr. political perspective: “I’m not a member of any party except the Cancer Party”

Oncologist biotech entrepreneur George Tidmarsh joins FDA as CDER director
His appointment came out of “proximity” to Makary and Bhattacharya